[A bioequivalence study in man of tablet and capsule formulations of the nonsteroidal anti-inflammatory compound 2-methoxyphenyl 1-methyl-5-(p-methylbenzoylpyrrol)-2-acetamidoacetate].
ST-679.(2-methoxyphenyl 1-methyl-5p-methylbenzoyl pyrrole-2-acetamide acetate) is a novel non-steroid anti-inflammatory agent consisting of tolmetin linked by an amide link to guaiacole-esterified glycine. The above reported study was aimed at to evaluation and comparison of pharmacokinetic parameters (Tmax, Cmax, AUC, t1/2 beta) of TGA, tolmetin, and MCPA in healthy volunteers after a single oral 600 mg tablet or capsule of ST-679 in order to assess the bioequivalence of the two formulations. The findings obtained show that pharmacokinetic parameters after administration of a 600 mg tablet are comparable to those after a 600 mg capsule. The two formulations may therefore be considered bioequivalent.